Uses of Posisva

Posisva 20 is used to treat hyperlipidemia or to prevent cardiovascular events in people at risk. The following article will provide readers with information about the uses, dosage and important notes during the treatment of Posisva.

Posisva 20 has the main ingredients:
Active ingredient: Pravastatin (as Pravastatin sodium): 20 mg Excipients: Lactose, wheat starch, Avicel, Povidon, PH 102, yellow iron oxide, red iron oxide, Polysorbate-80 , Magnesium stearate. Pravastatin competitively inhibits HMG-CoA reductase selectively, thereby inhibiting the conversion of 3-hydroxy-3-methylglutaryl Coenzyme A to Mevalonate. Mevalonate is a precursor form of sterols including cholesterol. Pravastatin helps to lower blood lipids through 2 mechanisms:
First, it is a competitive inhibitor of HMG-CoA reductase that reduces cholesterol synthesis, along with an increase in low-density lipoprotein receptors. LDL, increased catabolism and its clearance. Second: Pravastatin also inhibits LDL production by inhibiting the liver's synthesis of VLDL - cholesterol, a precursor of LDL-cholesterol. Since then, Pravastatin is effective in treating patients with hypercholesterolemia or people with mixed dyslipidemia. The drug lowers blood lipids, namely total cholesterol, LDL- cholesterol, apolipoprotein B, VLDL-cholesterol and triglycerides while HDL- cholesterol and apolipoprotein A remain elevated.
Meanwhile, clinical and pathological studies have shown that elevated plasma levels of total cholesterol, LDL- cholesterol and Apo B are a risk factor for cardiovascular diseases and fibrosis. vascular plaque.

2.1. Indications Posisva The drug Posisva is used as a supportive measure when diet and other non-pharmacological measures do not bring the desired effect.
Prevention of cardiovascular events includes:
In people without obvious cardiovascular disease: Prevention of myocardial infarction, reducing the risk of coronary revascularization, reducing the risk of cardiovascular death For For people with cardiovascular disease: reduce the risk of death from coronary heart disease, the risk of myocardial infarction, the risk of revascularization. Reduce the risk of transient ischemic attack or stroke. Slows the progression of atherosclerosis. Treatment of dyslipidemia:
Lowering total cholesterol, LDL-C, apo B and triglycerides as a combination with diet and other non-pharmacological therapies in people with primary or disordered hypercholesterolemia. mixed dyslipidemia. People with elevated serum triglycerides People with primary serum apolipoprotein B disorders. People with hypercholesterolemia, used in conjunction with diet and other non-pharmacological treatments. Treatment of elevated total cholesterol, LDL-C and apolipoprotein B in children due to heterozygous familial hypercholesterolemia. Medicines are used as adjuncts or substitutes when diet alone or the use of non-pharmacological therapies do not respond to treatment. 2.2. Contraindications Posisva drug Posisva drug is not used in the following cases:
People with advanced liver disease or increased levels of liver enzymes in the blood 3 times normal and prolonged without explanation. Pregnant or lactating women People with a history of hypersensitivity to Pravastain or any of the ingredients.

3.1.Usage : The drug Posisva 20 is used orally. Patients should take Posisva 20mg tablets whole, without chewing, breaking or crushing them, as this can reduce the effectiveness of the drug. The drug is administered in a single dose at any time of the day, regardless of the meal. Before starting Posisva 20, patients should rule out secondary causes of elevated cholesterol, use a standard diet low in cholesterol, and continue to maintain this diet throughout the treatment. treatment with Posisva. 3.2. Dosage: It is recommended to always start Posisva 20 from the lowest effective dose, then adjust the dose according to the needs and response of the individual patient. Assess response to treatment again after 4 weeks. During treatment and dose adjustment of Posisva 20, it is necessary to closely monitor side effects, especially those affecting the muscle system.
Adults:
Initial dose: 40 mg/time x 1 time/day, if no response can be increased to 80 mg/day. Patients with severe renal impairment start with dose: 10 mg/day Children and adolescents: dose depends on age:
8-13 years: 20 mg/time/day 14-18 years: 40 mg/time/day Do not use higher doses in these subjects. Immunosuppressive patients:
Recommended dose is 10 mg once daily at bedtime Consideration may be increased to 20 mg once daily People on clarithromycin: dose should be limited less than 40 mg/time/day

Pravastatin is well tolerated and has a lower discontinuation rate than other lipid-lowering agents. However, patients may experience some unwanted effects while using Posisva 20 such as:
Uncommon: dizziness, headache, sleep disturbance, vision disturbance, indigestion, abdominal pain , nausea, heartburn, flatulence; skin rash, myositis, cramps, paresthesia, rhinitis, arthralgia, muscle spasticity, muscle weakness, increased blood levels of CK,... Rare: peripheral polyneuritis, paresthesia, yellow skin, hepatitis, pancreatitis, hypersensitivity reactions,... If you experience unusual symptoms during treatment with Posisva, you should notify your doctor for instructions on how to handle it.

Posisva may interact if used concurrently with the following drugs and substances:
Fibrates such as Gemfibrozil or other drugs, Colchicin: increase muscle toxicity. Colestyramine: reduced bioavailability of pravastatin when co-administered. Cyclosporin: increases the concentration of pravastatin in the blood by 4 times, increasing the effect and prolonging the duration of action of the drug. Macrolide antibiotics such as erythromycin or clarithromycin: increased plasma concentrations and peak concentrations of pravastatin.

During the use of Posisva 20, patients should note:
Use caution when using the drug in patients with a history of liver disease or drinking a lot of alcohol. Check liver enzyme levels regularly, if elevated more than 3 times and persist, treatment should be stopped. Before initiating pravastatin therapy, hypercholesterolemia secondary to biliary cirrhosis, diabetes mellitus, nephrotic syndrome, and dysproteinemia must be excluded. It is necessary to test CK before treatment in the following cases: kidney failure, hypothyroidism, alcoholism, history of genetic diseases of the muscle system, people over 70 years old. If the test concentration is above 5 times normal, treatment should not be initiated and should be retested after 5-7 days. Patients should immediately notify the doctor if they have symptoms of muscle discomfort such as muscle pain, muscle stiffness, muscle weakness for timely support measures or consider stopping treatment. In cases of electrolyte disturbances, metabolic disorders, severe acute infections, hypotension, surgery or major trauma, it is necessary to temporarily discontinue or discontinue the drug, because of the risk of muscle damage, muscle wasting. People with a history of galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take Posisva, because the drug contains lactose. Posisva 20 does not affect the ability to drive and use machines. Posisva 20 should only be used in women of childbearing age after pregnancy has been definitively excluded and failure of other lipid-lowering treatments has been established. The drug is excreted in human milk in unspecified amounts, so caution should be exercised when using this drug in lactating women and nursing infants. Above is all information about Posisva 20 drug uses, dosage and important notes when using. Posisva 20 is a prescription drug, patients should consult their doctor if they have any questions to use the drug safely and effectively.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.